Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Monoaminergic neurotransmitter (serotonin, norepinephrine and dopamine) mechanisms of disease dominated the research landscape in the pathophysiology and treatment of major depressive disorder (MDD) for more than 50 years and still dominate available treatment options. However, the sum of all brain neurons that use monoamines as their primary neurotransmitter is <20 %. In addition, most patients treated with monoaminergic antidepressants are left with significant residual symptoms and psychosocial disability not to mention side effects, e.g., sexual dysfunction. In the past several decades, there has been greater focus on the major excitatory neurotransmitter in the human brain, glutamate, in the pathophysiology and treatment of MDD. Although several preclinical and human magnetic resonance spectroscopy studies had already implicated glutamatergic abnormalities in the human brain, it was rocketed by the discovery that the N-methyl-d-aspartate receptor antagonist ketamine has rapid and potent antidepressant effects in even the most treatment-resistant MDD patients, including those who failed to respond to electroconvulsive therapy and who have active suicidal ideation. In this review, we will first provide a brief introduction to glutamate and its receptors in the mammalian brain. We will then review the clinical evidence for glutamatergic dysfunction in MDD, the discovery and progress-to-date with ketamine as a rapidly acting antidepressant, and other glutamate receptor modulators (including proprietary medications) for treatment-resistant depression. We will finally conclude by offering potential future directions necessary to realize the enormous therapeutic promise of glutamatergic antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationThe Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 4×
“…by the translational inhibitor anisomycin, but not by the RNA polymerase/transcriptional inhibitor actinomycin D. Consistent with prior studies (Li et al. 2010, 2011), the antidepressant effects of ketamine could be prevented by pretreatment with NBQX, a…”
InfluentialNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 3×
“…mediator of ketamine’s antidepressant response in clinical studies (Gass et al. 2013). eEF2K/eEF2/BDNF In a second landmark preclinical mechanistic study, (Autry et al. 2011) reported that ketamine’s rapid antidepressant effects depended on desuppression of BDNF translation in the hippocampus.”
InfluentialMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 2×
“As detected by microdialysis, a medial PFC glutamate surge occurs with infusion of subanesthetic (10–30 mg/kg), but not higher-dose (50 and 200 mg/kg) ketamine on a time course consistent with mTOR activation (peaks within 30–60 min and returns to baseline at approximately 2 h) (Moghaddam et al. 1997).”
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“Taken together, the results suggest that mTOR activation via known intracellular second messenger/signal transduction mediators, e.g., MAPK/ERK and PI3K, is necessary for ketamine’s rapid antidepressant-like effects in rodents (Duman and Voleti 2012).”
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644 · cited 3×
“Excessive extrasynaptic glutamate receptor stimulation initiates apoptosis, and the physiological activity of EAAT2 theoretically reduces excitotoxicity from synaptic spillover in human brain (Hardingham and Bading 2010).”
InfluentialRajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477 · cited 2×
“decreased astroglial cell density in several brain regions, including orbitofrontal cortex, dorsolateral PFC (dlPFC) (Rajkowska et al. 1999), ACC (Cotter et al.”
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 2×
“The most obvious method of maintaining response involves multiple infusions, and this has proven efficacious in several reports (Murrough et al. 2011, 2013b; Blier et al. 2012).”
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 2×
“which is especially impressive considering the clinical heterogeneity of MDD (Shimizu et al. 2003; Kim et al. 2007).”
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“Several authors have proposed that the antidepressant effects of ketamine may depend on a rapid (within 30 min of administration) presynaptic glutamate ‘‘surge’’ and AMPA/NMDA receptor throughput in critical brain circuitry (Maeng et al. 2008).”
Self-citationLi, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
The -Catenin Destruction Complex
Stamos, J. L., & Weis, W. I. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007898 · Cited by 1,062 · cited 1×
“Phospho-GSK-3 interacts with a ‘‘destruction complex’’ of other proteins that target it for degradation in lysosomes, thereby allowing the transcription factor b-catenin to translocate from the cytosol to the nucleus and transcribe target genes (Stamos and Weis 2013).”
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 2×
“…increased glutamate/glutamine in the occipital cortex (Sanacora et al. 2004a), but decreased glutamate/glutamine levels in the prefrontal cortex (Hasler et al. 2007; Michael et al. 2003a), anterior cingulate cortex (Auer et al. 2000; Zhang et al. 2013b) and left amygdala (Michael et al. 2003b)…”
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 2×
“The most obvious method of maintaining response involves multiple infusions, and this has proven efficacious in several reports (Murrough et al. 2011, 2013b; Blier et al. 2012).”
Cotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
Duman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Perlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · cited 4×
“This latter finding has also been extended to acutely suicidal patients in the emergency department (Larkin and Beautrais 2011) as well as a reduction in both explicit and implicit measures of suicidal cognition (Price et al. 2009).”
InfluentialDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Self-citationSignaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537 · cited 1×
“Subsequent studies found that changes in peripheral BDNF (a major inducer of synaptic plasticity) were directly proportional to change from baseline slow-wave sleep electroencephalography (a surrogate marker of synaptic plasticity) in ketamine responders (Duncan et al. 2012).”
Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., & Brundin, L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.030 · Cited by 524 · cited 2×
“In a study of recently hospitalized medication-free suicide attempters in Sweden, quinolinic acid-to-kynurenic acid and interleukin-6 levels (Lindqvist et al. 2009) were increased in cerebrospinal fluid (CSF), and quinolinic acid levels correlated with increased scores on the Suicidal Intent Scale (Erhardt et al.”
Calcium Control of Neurotransmitter Release
Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011353 · Cited by 502 · cited 1×
“Glutamate release critically involves calcium influx (Sudhof 2012) and soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) and adapter proteins (Rizo and Sudhof 2012) to bridge the synaptic vesicle to the presynaptic membrane for exocytosis.”
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13 C NMR
Shen, J., Petersen, K. F., Behar, K. L., Brown, P., Nixon, T. W., Mason, G. F., Petroff, O. A. C., Shulman, G. I., Shulman, R. G., & Rothman, D. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8235 · Cited by 462 · cited 2×
“Consistent with glutamate’s key role in multiple aspects of brain physiology, metabolic studies have determined that almost all the glucose that enters the brain is ultimately converted to glutamate (Shen et al. 1999).”
Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421
Liu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Self-citationBernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., & Watson, S. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.44 · Cited by 372 · cited 2×
“…presynaptic vesicular glutamate transporters SLC17A6/VGLUT2 and postsynaptic glutamate receptors GRIA1, GRIK1, GRM1, and GRM5 are upregulated in MDD relative to bipolar disorder (BD) and non-depressed healthy volunteers (Bernard et al. 2011), alluding to both regional and diagnostic specificity.”
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Self-citationLow plasma BDNF is associated with suicidal behavior in major depression
Kim, Y.-K., Lee, H.-P., Won, S.-D., Park, E.-Y., Lee, H.-Y., Lee, B.-H., Lee, S.-W., Yoon, D., Han, C., Kim, D.-J., et al. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.024 · Cited by 300 · cited 2×
“which is especially impressive considering the clinical heterogeneity of MDD (Shimizu et al. 2003; Kim et al. 2007).”
Inflammation, Glutamate, and Glia in Depression:A Literature Review
McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289 · cited 2×
“understanding of inflammatory and glutamate cross-talk in depressive disorders (McNally et al. 2008).”
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 1×
“We also have preliminary evidence that dissociative side effects but not psychotomimetic or sympathomimetic side effects correlate with ketamine’s antidepressant effects (Luckenbaugh et al. 2013).”
Self-citationZarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Self-citationDeschwanden, A., Karolewicz, B., Feyissa, A. M., Treyer, V., Ametamey, S. M., Johayem, A., Burger, C., Auberson, Y. P., Sovago, J., Stockmeier, C. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.09111607 · Cited by 278
Salvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277 · cited 2×
“For instance, treatment-resistant MDD subjects with increased pretreatment rostral anterior cingulate cortex reactivity to fearful faces had an augmented antidepressant response to ketamine (Salvadore et al. 2009).”
Self-citationSynaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258
Liu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256 · cited 3×
“These include traditional antidepressants, mood stabilizers [because both ketamine and lithium are glycogen synthase kinase-3 (GSK-3) inhibitors (Liu et al. 2013)], antipsychotics [because of their efficacy as monotherapy in bipolar depression (Frye 2011) and as augmenting agents in MDD (Nelson and Papakostas 2009)],…”
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256 · cited 1×
“Subsequent studies found that changes in peripheral BDNF (a major inducer of synaptic plasticity) were directly proportional to change from baseline slow-wave sleep electroencephalography (a surrogate marker of synaptic plasticity) in ketamine responders (Duncan et al. 2012).”
Self-citationZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
Self-citationPlasma kynurenine levels are elevated in suicide attempters with major depressive disorder
Sublette, M. E., Galfalvy, H. C., Fuchs, D., Lapidus, M., Grunebaum, M. F., Oquendo, M. A., John Mann, J., & Postolache, T. T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.002 · Cited by 250 · cited 2×
“Plasma kynurenic acid levels are increased in MDD patients with a history of suicide attempt relative to MDD patients without a history of suicide and non-psychiatric healthy volunteers (Sublette et al. 2011).”
Ibrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 3×
“In the only randomized, placebo-controlled extension trial after a single subanesthetic infusion, approximately 27 % of ketamine responders maintained efficacy during the 28-day follow- up period (average time to relapse = 13.2 days; standard error of the mean = 2.2) (Ibrahim et al. 2012b).”
InfluentialSelf-citationMathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220 · cited 1×
“…development in new diagnostic tools and, most importantly, offered effective alternative treatment options for even the most refractory patients (Mathews et al. 2012), including those with electroconvulsive therapy (ECT) resistant symptoms (Ibrahim et al. 2011) and active suicidal thoughts…”
Self-citationLaje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213 · cited 1×
“Laje et al. (2012) identified the BDNF val66met rs6265 SNP as a predictor of ketamine response; in that study, BDNF val/val homozygotes (n = 41) had a better antidepressant response to ketamine than the met haplotype (n = 21).”
Self-citationPalmer, C. L., Cotton, L., & Henley, J. M. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.7 · Cited by 211 · cited 2×
“AMPA/ kainate receptor activation mediates the fast (due to Na? influx) component (Palmer et al. 2005) while NMDA receptor activation produces a more delayed and prolonged excitation (via Ca2? influx).”
Coverage of Blood Vessels by Astrocytic Endfeet Is Reduced in Major Depressive Disorder
Rajkowska, G., Hughes, J., Stockmeier, C. A., Javier Miguel-Hidalgo, J., & Maciag, D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.024 · Cited by 209 · cited 1×
“There is also a significant reduction in aquaporinimmunoreactive astrocytic end-feet contacting gray matter vessels in MDD PFC, which also implicates blood–brain barrier abnormalities in MDD (Rajkowska et al. 2013).”
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177 · cited 1×
“A larger trial of 26 treatment-resistant MDD patients (by the same group and with the same design) used escalating doses of adjuvant DCS up to 1,000 mg/day (Heresco-Levy et al. 2013).”
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Self-citationMachado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Self-citationSerum markers support disease-specific glial pathology in major depression
Schroeter, M. L., Abdul-Khaliq, H., Krebs, M., Diefenbacher, A., & Blasig, I. E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.005 · Cited by 152
Chowdhury, G. M. I., Behar, K. L., Cho, W., Thomas, M. A., Rothman, D. L., & Sanacora, G. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.006 · Cited by 125
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89 · cited 2×
“…6-week, placebo-controlled, cross-over trial of 250 mg/day as an add-on in treatment-resistant MDD, DCS provided depressive symptom reduction but did not separate from placebo (p = 0.51) due to a burst in improvement in the placebo group in the final week of the study (Heresco-Levy et al. 2006).”
InfluentialBaseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder
Duncan, W. C., Selter, J., Brutsche, N., Sarasso, S., & Zarate, C. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.042 · Cited by 86
Self-citationTaylor, M. J., Tiangga, E. R., Mhuircheartaigh, R. N., & Cowen, P. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405359 · Cited by 66
On the safety and benefits of repeated intravenous injections of ketamine for depression.
Blier, P., Zigman, D., & Blier, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.039 · Cited by 64 · cited 1×
“The most obvious method of maintaining response involves multiple infusions, and this has proven efficacious in several reports (Murrough et al. 2011, 2013b; Blier et al. 2012).”
Lenze, E. J., Skidmore, E. R., Begley, A. E., Newcomer, J. W., Butters, M. A., & Whyte, E. M. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2813 · Cited by 63 · cited 2×
“small, placebo-controlled, 12-week trial in depressed older patients who had recently suffered a disabling medical event confirmed memantine’s lack of efficacy on depressive symptoms and functional outcomes (Lenze et al. 2012).”
Ketamine regulates the presynaptic release machinery in the hippocampus
Müller, H. K., Wegener, G., Liebenberg, N., Zarate, C. A., Popoli, M., & Elfving, B. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.008 · Cited by 61
Self-citationZanicotti, C. G., Perez, D., & Glue, P. (2012) · Journal of Palliative Medicine · doi:10.1089/jpm.2011.0314 · Cited by 52 · cited 1×
“Non-intravenous ketamine preparations such as oral (Irwin and Iglewicz 2010; McNulty and Hahn 2012) and intramuscular (Zanicotti et al. 2012; Cusin et al. 2012) have also shown antidepressant efficacy.”
Lee, S.-Y., Chen, S.-L., Chang, Y.-H., Chen, S.-H., Chu, C.-H., Huang, S.-Y., Tzeng, N.-S., Wang, C.-L., Lee, I. H., Yeh, T. L., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.024 · Cited by 35 · cited 2×
“…(Lauterbach 2011, 2012): there have been no randomized controlled trials of dextromethorphan as monotherapy for the treatment of depressive disorders [although it has been studied in a randomized, placebo-controlled trial add-on to valproic acid in bipolar disorder (Lee et al. 2012)].”
Khundakar, A. A., Morris, C. M., Oakley, A. E., & Thomas, A. J. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.04.008 · Cited by 29 · cited 2×
“2000), but not in the supragenual ACC in later-life depression (Khundakar et al. 2011).”
Research works printed but not linked: 113
- Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R (2012) Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT 28:157–161 · DOI · Paper page
- Albensi BC, Mattson MP (2000) Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 35:151–159 · DOI · Paper page
- Altshuler LL, Abulseoud OA, Foland-Ross L, Bartzokis G, Chang S, Mintz J, Hellemann G, Vinters HV (2010) Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord 12:541–549 · DOI · Paper page
- Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000) Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47:305–313 · DOI · Paper page
- Barley K, Dracheva S, Byne W (2009) Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr Res 112:54–64 · DOI
- Bartoc C, Frumento RJ, Jalbout M, Bennett-Guerrero E, Du E, Nishanian E (2006) A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients. J Cardiothorac Vasc Anesth 20:217–222 · DOI
- Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A, Matthews PM, Cowen PJ (2007) Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61:806–812 · DOI · Paper page
- Bowley MP, Drevets WC, Ongur D, Price JL (2002) Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52:404–412 · DOI · Paper page
- Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Manji HK, Zarate CA Jr, Drevets WC (2013) Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry 73:1213–1221 · DOI · Paper page
- Carvalho AF, Macedo DS, Goulia P, Hyphantis TN (2013) N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression. J Clin Psychopharmacol 33:719–720 · DOI · Paper page
- Chan MH, Chiu PH, Lin CY, Chen HH (2012) Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine. Schizophr Res 136:96–103 · DOI
- Chepenik LG, Fredericks C, Papademetris X, Spencer L, Lacadie C, Wang F, Pittman B, Duncan JS, Staib LH, Duman RS, Gelernter J, Blumberg HP (2009) Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. Neuropsychopharmacology 34:944–951 · DOI · Paper page
- Cho JE, Shim JK, Choi YS, Kim DH, Hong SW, Kwak YL (2009) Effect of low-dose ketamine on inflammatory response in off-pump coronary artery bypass graft surgery. Br J Anaesth 102:23–28 · DOI
- Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102:15653–15658 · DOI · Paper page
- Cokic B, Stein V (2008) Stargazin modulates AMPA receptor antagonism. Neuropharmacology 54:1062–1070 · DOI
- Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, Zarate CA Jr (2012) Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 72:555–561 · DOI · Paper page
- Cusin C, Hilton GQ, Nierenberg AA, Fava M (2012) Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 169:868–869 · DOI
- de Carvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28:445–452 · DOI
- De Rosa SC, Zaretsky MD, Dubs JG, Roederer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjioe I, Deresinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA, Herzenberg LA (2000) N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 30:915–929 · DOI · Paper page
- Denk MC, Rewerts C, Holsboer F, Erhardt-Lehmann A, Turck CW (2011) Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry 168:751–752 · DOI
- Diaz E (2010) Regulation of AMPA receptors by transmembrane accessory proteins. Eur J Neurosci 32:261–268 · DOI · Paper page
- Diniz BS, Teixeira AL, Miranda AS, Talib LL, Gattaz WF, Forlenza OV (2012) Circulating Glial-derived neurotrophic factor is reduced in late-life depression. J Psychiatr Res 46:135–139 · DOI
- Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384:505–516 · DOI · Paper page
- Fatemi SH, Laurence JA, Araghi-Niknam M, Stary JM, Schulz SC, Lee S, Gottesman II (2004) Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res 69:317–323 · DOI · Paper page
- Frye MA (2011) Clinical practice. Bipolar disorder—a focus on depression. N Engl J Med 364:51–59 · DOI · Paper page
- Gass N, Schwarz AJ, Sartorius A, Schenker E, Risterucci C, Spedding M, Zheng L, Meyer-Lindenberg A, Weber-Fahr W (2013) Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology. [Epub ahead of print] · DOI
- Ghasemi M, Raza M, Dehpour AR (2010) NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacol 24:585–594 · DOI · Paper page
- Gutierrez H, Davies AM (2011) Regulation of neural process growth, elaboration and structural plasticity by NF-kappaB. Trends Neurosci 34:316–325 · DOI · Paper page
- Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, Zarate CA Jr (2011) Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 35:1155–1159 · DOI · Paper page
- Irwin SA, Iglewicz A (2010) Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 13:903–908 · DOI · Paper page
- Jarventausta K, Chrapek W, Kampman O, Tuohimaa K, Bjorkqvist M, Hakkinen H, Yli-Hankala A, Leinonen E (2013) Effects of s-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT 29:158–161 · DOI · Paper page
- Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241:835–837 · DOI · Paper page
- Knott VJ, Millar AM, McIntosh JF, Shah DK, Fisher DJ, Blais CM, Ilivitsky V, Horn E (2011) Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. Biol Psychol 88:83–93 · DOI
- Koga K, Ogata M, Takenaka I, Matsumoto T, Shigematsu A (1994) Ketamine suppresses tumor necrosis factor-alpha activity and mortality in carrageenan-sensitized endotoxin shock model. Circ Shock 44:160–168
- Kollmar R, Markovic K, Thurauf N, Schmitt H, Kornhuber J (2008) Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry 42:170 · DOI
- Kranaster L, Kammerer-Ciernioch J, Hoyer C, Sartorius A (2011) Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 261:575–582 · DOI
- Krystal AD, Weiner RD, Dean MD, Lindahl VH, Tramontozzi LA 3rd, Falcone G, Coffey CE (2003a) Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci 15:27–34 · doi:10.1176/jnp.15.1.27 · Paper page
- Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D’Souza DC, Boutros NN, Trevisan L, Charney DS (2003b) Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology 28:2020–2028 · DOI
- Kupfer DJ, Frank E, McEachran AB, Grochocinski VJ (1990) Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder. Arch Gen Psychiatry 47:1100–1105 · DOI · Paper page
- Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6:869–872 · DOI · Paper page
- Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9–19 · DOI · Paper page
- Larkin GL, Beautrais AL (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14(8):1127–1131 · DOI · Paper page
- Lauterbach EC (2011) Dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses 76:717–719 · DOI
- Lauterbach EC (2012) An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses 78:693–702 · DOI
- Liu Q, Zhu HY, Li B, Wang YQ, Yu J, Wu GC (2012a) Chronic clomipramine treatment restores hippocampal expression of glial cell line-derived neurotrophic factor in a rat model of depression. J Affect Disord 141:367–372 · DOI
- Loo CK, Katalinic N, Garfield JB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R (2012) Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord 142:233–240 · DOI
- Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr (2012) Family history of alcohol dependence and antidepressant response to an N-methyl-d-aspartate antagonist in bipolar depression. Bipolar Disord 14:880–887 · DOI · Paper page
- Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS (2009) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13:71–82 · DOI · Paper page
- McNulty JP, Hahn K (2012) Compounded oral ketamine. Int J Pharm Compd 16:364–368
- Messer M, Haller IV, Larson P, Pattison-Crisostomo J, Gessert CE (2010) The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci 22:442–444 · doi:10.1176/jnp.2010.22.4.442 · Paper page
- Messias E, Everett B (2012) Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report. Prim Care Companion CNS Disord 14. doi: 10.4088/PCC.12l01400 · DOI
- Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B (2003a) Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 33:1277–1284 · DOI · Paper page
- Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B (2003b) Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 28:720–725 · DOI · Paper page
- Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Rajkowska G (2000) Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 48:861–873 · DOI · Paper page
- Millan MJ (2002) N-methyl-d-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurological Disord 1:191–213 · DOI · Paper page
- Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK (2005) Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 25:6389–6393 · DOI · Paper page
- Muhonen LH, Lahti J, Sinclair D, Lonnqvist J, Alho H (2008a) Treatment of alcohol dependence in patients with co-morbid major depressive disorder—predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy 3:20 · DOI · Paper page
- Muhonen LH, Lonnqvist J, Juva K, Alho H (2008b) Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 69:392–399 · DOI · Paper page
- Murck H, Schubert MI, Schmid D, Schussler P, Steiger A, Auer DP (2009) The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression—an MR spectroscopy study. J Psychiatr Res 43:175–180 · DOI
- Murrough JW, Perez AM, Mathew SJ, Charney DS (2011) A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry 72:414–415 · DOI · Paper page
- Musazzi L, Treccani G, Mallei A, Popoli M (2013) The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry 73:1180–1188 · DOI · Paper page
- Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–991 · DOI · Paper page
- Niciu MJ, Kelmendi B, Sanacora G (2012) Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav 100:656–664 · DOI · Paper page
- Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A (1984) Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307:462–465 · DOI · Paper page
- Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Drevets WC, Zarate CA Jr. (2013) Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. [Epub ahead of print] · DOI · Paper page
- Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T (2010) Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT 26:223–227 · DOI · Paper page
- Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN (2000) The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22:293–302 · DOI
- Ostroff R, Gonzales M, Sanacora G (2005) Antidepressant effect of ketamine during ECT. Am J Psychiatry 162:1385–1386 · DOI
- Pallavi P, Sagar R, Mehta M, Sharma S, Subramanium A, Shamshi F, Sengupta U, Qadri R, Pandey RM, Mukhopadhyay AK (2013) Serum neurotrophic factors in adolescent depression: gender difference and correlation with clinical severity. J Affect Disord 150:415–423 · DOI
- Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Rybakowski JK (2013) Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 46:227–228 · DOI · Paper page
- Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, Gelernter J, Krystal JH (2004) Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry 161:1776–1782 · DOI · Paper page
- Pfleiderer B, Michael N, Erfurth A, Ohrmann P, Hohmann U, Wolgast M, Fiebich M, Arolt V, Heindel W (2003) Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 122:185–192 · DOI · Paper page
- Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr (2009) Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biol Psychiatry 65:181–184 · DOI · Paper page
- Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631–637 · DOI · Paper page
- Rizo J, Sudhof TC (2012) The membrane fusion enigma: SNAREs, Sec1/Munc18 proteins, and their accomplices—guilty as charged? Annu Rev Cell Dev Biol 28:279–308 · DOI · Paper page
- Rogawski MA (2011) Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11:56–63 · DOI · Paper page
- Roytblat L, Talmor D, Rachinsky M, Greemberg L, Pekar A, Appelbaum A, Gurman GM, Shapira Y, Duvdenani A (1998) Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. Anesth Analg 87:266–271 · DOI · Paper page
- Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689–701 · DOI · Paper page
- Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A (2013) Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol 28:87–90 · DOI · Paper page
- Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF (2003) Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53:1028–1042 · DOI · Paper page
- Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, Holroyd T, DiazGranados N, Machado-Vieira R, Grillon C, Drevets WC, Zarate CA Jr (2010) Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:1415–1422 · DOI · Paper page
- Salvadore G, van der Veen JW, Zhang Y, Marenco S, Machado-Vieira R, Baumann J, Ibrahim LA, Luckenbaugh DA, Shen J, Drevets WC, Zarate CA (2011) An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 15(8):1063–1072 · DOI · Paper page
- Salvadore G, van der Veen JW, Zhang Y, Marenco S, Machado-Vieira R, Baumann J, Ibrahim LA, Luckenbaugh DA, Shen J, Drevets WC, Zarate CA Jr (2012) An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 15:1063–1072 · DOI · Paper page
- Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF (2004a) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61:705–713 · DOI · Paper page
- Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH (2004b) Riluzole augmentation for treatment-resistant depression. Am J Psychiatry 161:2132 · DOI
- Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH (2007) Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61:822–825 · DOI · Paper page
- Schulz D, Smith D, Yu M, Lee H, Henn FA (2013) Selective breeding for helplessness in rats alters the metabolic profile of the hippocampus and frontal cortex: a 1H-MRS study at 9.4 T. Int J Neuropsychopharmacol 16:199–212 · DOI
- Seese RR, Chen LY, Cox CD, Schulz D, Babayan AH, Bunney WE, Henn FA, Gall CM, Lynch G (2013) Synaptic abnormalities in the infralimbic cortex of a model of congenital depression. J Neurosci 33:13441–13448 · DOI · Paper page
- Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T (2013) Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 34(4):287–293
- Stahl SM (2010) Psychiatric stress testing: novel strategy for translational psychopharmacology. Neuropsychopharmacology 35:1413–1414 · DOI
- Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379 · DOI · Paper page
- Su N, Zhang L, Fei F, Hu H, Wang K, Hui H, Jiang XF, Li X, Zhen HN, Li J, Cao BP, Dang W, Qu Y, Zhou F (2011) The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res 1415:119–126 · DOI
- Suliburk JW, Helmer KS, Gonzalez EA, Robinson EK, Mercer DW (2005) Ketamine attenuates liver injury attributed to endotoxemia: role of cyclooxygenase-2. Surgery 138:134–140 · DOI
- Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ (2012) The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. J Clin Psychiatry 73:967–976 · DOI
- Takamori S (2006) VGLUTs: ‘exciting’ times for glutamatergic research? Neurosci Res 55:343–351 · DOI · Paper page
- Taniguchi T, Shibata K, Yamamoto K (2001) Ketamine inhibits endotoxin-induced shock in rats. Anesthesiology 95:928–932 · DOI
- Taniguchi T, Takemoto Y, Kanakura H, Kidani Y, Yamamoto K (2003) The dose-related effects of ketamine on mortality and cytokine responses to endotoxin-induced shock in rats. Anesth Analg 97:1769–1772 · DOI
- Taniguchi T, Kanakura H, Takemoto Y, Yamamoto K (2004) The antiinflammatory effects of ketamine in endotoxemic rats during moderate and mild hypothermia. Anesth Analg 98:1114–1120 · doi:10.1213/01.ane.0000100740.07331.a2
- Taylor M, Murphy SE, Selvaraj S, Wylezinkska M, Jezzard P, Cowen PJ, Evans J (2008) Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J Psychopharmacol 22:473–476 · DOI · Paper page
- Taylor MJ, Norbury R, Murphy S, Rudebeck S, Jezzard P, Cowen PJ (2010) Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. J Psychopharmacol 24:1217–1221 · DOI
- Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57:1139–1147 · DOI · Paper page
- Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191:122–127 · DOI · Paper page
- Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C (2012) Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT 28:128–132 · DOI · Paper page
- Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH (2009) Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. Int J Neuropsychopharmacol 12:357–370 · DOI · Paper page
- Welters ID, Hafer G, Menzebach A, Muhling J, Neuhauser C, Browning P, Goumon Y (2010) Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappaB, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines. Anesth Analg 110:934–941 · DOI · Paper page
- Yuksel C, Ongur D (2010) Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 68:785–794 · DOI · Paper page
- Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161:171–174 · DOI · Paper page
- Zarate CA Jr, Mathews DC, Furey ML (2013b) Human biomarkers of rapid antidepressant effects. Biol Psychiatry 73:1142–1155 · DOI · Paper page
- Zhang X, Zhang Z, Xie C, Xi G, Zhou H, Zhang Y, Sha W (2008) Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 32:886–890 · DOI
- Zhang X, Zhang Z, Sha W, Xie C, Xi G, Zhou H, Zhang Y (2009) Electroconvulsive therapy increases glial cell-line derived neurotrophic factor (GDNF) serum levels in patients with drug-resistant depression. Psychiatry Res 170:273–275 · DOI
- Zhang C, Li Z, Wu Z, Chen J, Wang Z, Peng D, Hong W, Yuan C, Wang Z, Yu S, Xu Y, Xu L, Xiao Z, Fang Y (2013a) A study of N-methyl-d-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology (Berl). [Epub ahead of print] · DOI
- Zhang J, Narr KL, Woods RP, Phillips OR, Alger JR, Espinoza RT (2013b) Glutamate normalization with ECT treatment response in major depression. Mol Psychiatry 18:268–270 · DOI · Paper page
- Zhou Z, Wu J, Yang C (2011) Concerns about dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses 77:309–310 · DOI
Cited by
Barth, C., Villringer, A., & Sacher, J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00037 · Cited by 711
Inflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
“Gln is released by astrocytes into presynaptic neurons where it is converted back to Glu by cytosolic glutaminase (15,16).”
Self-citationGlutamatergic Mechanisms Associated with Seizures and Epilepsy
Barker-Haliski, M., & White, H. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022863 · Cited by 442
The Role of Magnesium in Neurological Disorders
Kirkland, A. E., Sarlo, G. L., & Holton, K. F. (2018) · Nutrients · doi:10.3390/nu10060730 · Cited by 382
“Anxiety and depression are also similarly mediated by altered glutamatergic neurotransmission, which may account for this comorbidity [68,69].”
Background
Metadata
- Authors
- Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A.
- Venue
- Journal of Neural Transmission
- Published
- 2013-12-08
- Volume
- 121
- Issue
- 8
- Pages
- 907-924
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2073079805
- Cited by
- 155
- References
- 66
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.